- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00054262
T900607 in Treating Patients With Unresectable Liver Cancer
A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have unresectable liver cancer.
Study Overview
Detailed Description
OBJECTIVES:
- Determine the complete and partial response rates of patients with chemotherapy-naïve unresectable hepatocellular carcinoma treated with T900607.
- Determine the efficacy of this drug, in terms of duration of response and time to disease progression, in these patients.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the safety profile of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive T900607 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-1714
- Ireland Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed unresectable hepatocellular carcinoma (HCC)
- Bidimensionally measurable disease defined as at least 1 lesion that is 1 cm or more in 2 dimensions by CT scan
- Class A or B Child-Pugh liver classification
- No prior CNS metastases or carcinomatous meningitis
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Karnofsky 70-100%
Life expectancy
- At least 12 weeks
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3*
- Platelet count at least 100,000/mm^3*
- Hemoglobin at least 8.5 g/dL* NOTE: *More than 7 days since prior blood transfusions or growth factors
Hepatic
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- Albumin greater than 2.5 g/dL
- AST and ALT no greater than 3 times ULN
- INR no greater than 1.5 (unless receiving anticoagulants)
Renal
- Creatinine no greater than 2 times ULN
Cardiovascular
- LVEF at least 50%
- No New York Heart Association class III or IV cardiac disease
- No acute anginal symptoms
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study
- No severe concurrent disease, infection, or co-morbidity that would preclude study entry
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior immunotherapy for HCC
- No concurrent therapeutic biological response modifier
Chemotherapy
- No prior chemotherapy for HCC
- No prior chemoembolization for HCC
- No other concurrent cytotoxic chemotherapy
Endocrine therapy
- At least 6 weeks since prior hormonal therapy (an indicator lesion must exist outside the area of therapy
- No concurrent hormonal anticancer therapy
Radiotherapy
- No prior radiotherapy for HCC
- At least 6 weeks since prior radiofrequency ablation, selective internal radiation, or embolization (an indicator lesion must exist outside the area of therapy)
- No concurrent radiotherapy (including palliative therapy)
Surgery
At least 6 weeks since prior surgical resection (an indicator lesion must exist outside the area of therapy)
- Recurrence at the margin of the surgical resection is allowed
- At least 6 weeks since prior cryosurgery
- More than 4 weeks since other prior major surgery
Other
- More than 4 weeks since prior investigational therapy
- At least 6 weeks since prior intratumoral ethanol injection (an indicator lesion must exist outside the area of therapy)
- No other concurrent investigational anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Joanna M. Brell, MD, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TULA-TULI-2202
- CWRU-100211
- CDR0000270198 (Registry Identifier: PDQ (Physician Data Query))
- TULA-T-607-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cancer
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Duke UniversityCompletedPrimary Liver Cancer | Metastatic Liver Cancer From Any Cancer SiteUnited States
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
Célia TurcoCompletedPrimary Liver Cancer | Liver Metastases | Secondary Liver CancerFrance
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Radboud University Medical CenterTerumo Medical CorporationCompletedPrimary Liver Cancer | Liver Cancer | Liver Metastasis Colon CancerNetherlands
-
Cardiovascular and Interventional Radiological...RecruitingPrimary Liver Cancer | Secondary Liver CancerGermany
-
Shanghai Huihe Medical Technology Co., LtdEnrolling by invitation
-
Burzynski Research InstituteTerminatedPrimary Liver CancerUnited States
Clinical Trials on T900607
-
TularikTerminatedNon-Hodgkin's LymphomaUnited States
-
TularikUnknownHepatocellular CarcinomaUnited States, China
-
University Hospitals Seidman Cancer CenterNational Cancer Institute (NCI)Completed
-
TularikUnknownOvarian NeoplasmsUnited States
-
TularikSuspendedGastric Cancer | Esophageal NeoplasmsUnited States